IBRNvsBBPETF Comparison
VS
iShares Neuroscience and Healthcare ETF (IBRN) belongs to the Healthcare Technology segment. Virtus LifeSci Biotech Products ETF (BBP) is part of the Tomorrow's Treatments segment. IBRN's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, BBP's top sector exposures are Healthcare. IBRN is more expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.34% for BBP. IBRN is up 20.57% year-to-date (YTD) with +$2M in YTD flows. BBP performs better with 34.57% YTD performance, and +$50M in YTD flows. Run a side-by-side ETF comparison of IBRN and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN vs BBP performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/01/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN BBP | +6.36%+14.04% | +10.03%+27.03% | +20.57%+34.57% | +55.97%+55.56% | +69.91%+99.31% | n/a+101.45% |
| Flows | IBRN BBP | +$2M+$5M | +$2M+$20M | +$2M+$50M | +$2M+$62M | +$759K+$68M | -+$58M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN BBP | +26.38%+26.23% | +25.83%+25.04% | +25.21%+24.70% | n/a+26.59% |
| Max drawdown | IBRN BBP | -9.28%-9.34% | -9.28%-9.59% | -34.98%-25.54% | n/a-37.61% |
| Max drawdown duration | IBRN BBP | 40d39d | 40d48d | 338d292d | n/a586d |
Trading data
IBRN | BBP | |
Last sale 9/2/2026 at 1:30 PM | $39.46 | $109.66 |
| Previous close 09/01/2026 | $38.94 | $107.37 |
| Consolidated volume 09/01/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/2/2026 at 1:30 PM
Live
Closed
IBRN | BBP | |
|---|---|---|
| Last price | $39.46 | $109.66 |
| 1D performance | +1.33% | +2.13% |
| AuM | $7.79 M | $118.07 M |
| E/R | 0.47% | 0.34% |
Characteristics
IBRN | BBP | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | iShares | VIRTUS Investment Partners |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | LifeSci Biotechnology Products Index |
| N° of holdings | 69 | 66 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
IBRN
USA
73.57%
Other
26.43%
BBP
USA
86.5%
Other
13.5%
Sectors
IBRN
Healthcare
99.87%
Other
0.13%
BBP
Healthcare
98.2%
Other
1.8%
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
64.26%
BBP
Total weight of top 15 holdings out of 15
26.78%
Top 15 holdings
Data as of July 31, 2026
IBRN
Dianthus Therapeutics, Inc.
5.45%
Xenon Pharmaceuticals, Inc.
4.83%
Praxis Precision Medicines, Inc.
4.72%
ACADIA Pharmaceuticals, Inc.
4.66%
Arrowhead Pharmaceuticals, Inc.
4.65%
Alkermes Plc
4.55%
Neurocrine Biosciences, Inc.
4.41%
Scholar Rock Holding Corp.
4.31%
PTC Therapeutics, Inc.
4.15%
Biogen, Inc.
4.15%
Axsome Therapeutics, Inc.
3.93%
argenx SE
3.82%
Denali Therapeutics, Inc.
3.76%
Dyne Therapeutics, Inc.
3.53%
Edgewise Therapeutics, Inc.
3.35%
BBP
Crinetics Pharmaceuticals, Inc.
3.24%
Verastem, Inc.
1.98%
Nuvation Bio, Inc.
1.80%
Omeros Corp.
1.73%
Geron Corp.
1.72%
BridgeBio Pharma, Inc.
1.68%
Agios Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
BeOne Medicines Ltd.
1.64%
Kiniksa Pharmaceuticals International Plc
1.63%
Precigen, Inc.
1.62%
Xeris Biopharma Holdings, Inc.
1.61%
ACADIA Pharmaceuticals, Inc.
1.60%
Iovance Biotherapeutics, Inc.
1.60%
Rhythm Pharmaceuticals, Inc.
1.60%
Frequently asked questions about IBRN and BBP
How have the IBRN and BBP ETFs performed in 2026?
As of September 1, 2026, IBRN is up 20.57% year-to-date (YTD), while BBP has returned 34.57%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: IBRN or BBP?
Year-to-date, the IBRN ETF saw +$2M in flows, compared to +$50M for BBP.
Which ETF is more volatile: IBRN or BBP?
Over the past year, IBRN had a volatility of 25.83%, while BBP experienced 25.04%.
Which ETF is bigger: IBRN or BBP?
As of September 1, 2026, IBRN holds $7.79 M in assets under management (AUM), while BBP manages $118.07 M.
What sectors do the IBRN and BBP ETFs invest in?
IBRN leans toward sectors like Healthcare. Meanwhile, BBP focuses on Healthcare.
What are the top holdings of the IBRN ETF and BBP ETF?
IBRN top holdings include Dianthus Therapeutics, Inc., Xenon Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc.. BBP holds in its top three: Crinetics Pharmaceuticals, Inc., Verastem, Inc. and Nuvation Bio, Inc..
Which ETF is more diversified: IBRN or BBP?
IBRN holds 69 securities with 64.26% of its assets in the top 15. BBP has 66 securities and a top 15 weight of 26.78%.
Advertisement
Advertisement
